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ABSTRACT 
 
Lentiviruses translate their structural and enzymatic proteins from unspliced and singly 
spliced viral mRNAs (vRNAs). Export to the cytoplasm of the incompletely spliced transcripts is 
mediated by the viral Rev protein. Rev binds to a highly structured region of the unspliced/singly 
spliced RNA, termed the Rev responsive element (RRE), multimerizes, and tethers the RNA to 
cellular export factors to cross the nuclear membrane. While Rev-RRE mediated nuclear export 
is well studied in human immunodeficiency virus type 1 (HIV-1), the interaction between the 
equine infectious anemia virus (EIAV) Rev and the RRE is less well studied. Chemical 
footprinting analysis indicates Rev interacts with two regions on the RNA, termed Rev binding 
region one (RBR-1) and Rev binding region 2 (RBR-2). RBR-1 contains a 56nt sequence termed 
the minRRE sufficient to both bind Rev and support nuclear export. The minRRE spans Rev 
exon 1 and an exon splicing enhancer (ESE) necessary for Rev exon 1 splicing. RBR-2 was 
previously functionally uncharacterized. RBR-2 contains predicted structural motifs found in 
several other lentiviruses, and is required for Rev high affinity binding, suggesting this region is 
biologically relevant and may be involved in Rev nuclear export.  Here we examined the effect 
of deleting RBR-2 on nuclear export, virus structural gene expression, and virion production, and 
Rev-SF2/ASF competition. Our findings indicate RBR-2 is neither necessary nor sufficient for 
nuclear export, and deletion of RBR-2 does not affect either virus structural gene expression or 
virion production, suggesting RBR-1 is the primary binding site and RRE for Rev. The RBR-1 
sequence secondary structure and the genomic intronic location is distinct from that of HIV-1 
and other lentivirus RREs. It is still unclear if RBR-2 has a functional role in virus replication.
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CHAPTER 1. GENERAL INTRODUCTION 
 
Thesis Organization 
 
 This thesis is a functional analysis of an RNA element important in the equine infectious 
anemia virus (EIAV) Rev nuclear export pathway. This thesis has three chapters and one 
appendix. Chapter one is a literature review that provides background information on 
retroviruses and EIAV, alternative splicing and the role of Rev in alternative splicing, and what 
is currently known about the Rev-RRE interaction in EIAV. Chapter two describes the functional 
analysis of RNA sequences important in Rev activity and is formatted for submission to the 
Journal of General Virology. The manuscript was co-authored by Jerald Chavez, Hyelee Loyd, 
Drena Dobbs and Susan Carpenter. I carried out experimental procedures, assisted in the design 
of experiments and interpretation of results, and am responsible for writing the manuscript. 
Hyelee Loyd assisted in the construction of the pERRE-1B and pERRE-1C plasmid clones. 
Drena Dobbs assisted in design of experiments and critical analysis of results. Susan Carpenter 
assisted in design of experiments, interpretation of results, and editing of the manuscript.  
Chapter three summarizes the project and potential future studies that could be performed. The 
appendix includes computational analysis of the RNA binding residues for various EIAV Rev 
amino acid variants. 
Introduction 
Retroviruses 
The retrovirus family consists of seven different subfamilies grouped by similarity in 
morphology and genetic relatedness. All retroviruses consist of two copies of the positive sense 
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RNA genome surrounded by an inner protein capsid and outer membrane envelope (Figure 1, 
(1)).  While retroviruses can differ by the presence or absence of accessory and regulatory genes, 
all retroviral genomes contain three specific genes: gag, pol, and env. The gag gene encodes 
interior structural proteins including the matrix, capsid and nucleocapsid proteins while pol 
encodes the enzymatic proteins including reverse transcriptase, protease, and integrase. Finally, 
env encodes the structural proteins of the envelope, including the surface unit (SU) and 
transmembrane protein (TM). Like all viruses, retroviruses must enter a cell, replicate their 
genome and protein components, assemble into new virions, and exit the infected cell. Entry is 
mediated by the SU proteins of the envelope upon interaction with their target cell membrane 
receptors. TM anchors the viral envelope proteins to the viral membrane, and also serves to 
initiate fusion of the viral membrane with target host cell membrane. This will release the viral 
core capsid and genome into the interior of the cell. The viral reverse transcriptase converts the 
RNA genome into a DNA form termed the provirus, which is integrated into the host cell 
genome via integrase. Cellular polymerases transcribe the viral genes and upon translation, new 
viral RNA genomes and proteins assemble and bud off from the cell. The viral protease cleaves 
the Gag-Pol polyproteins into their individual proteins, making the virions mature and ready to 
infect new cells.  
Lentiviruses and Alternative Splicing 
 Lentiviruses are one of seven subfamilies of the larger retrovirus family. “Lenti” in latin 
means slow and refers to the slow progression of the disease course that many in this virus class 
are known for, including human immunodeficiency virus type 1 (HIV-1). Retrovirus genomes 
are relatively small (8-10kb), and as such, utilize a number of strategies to maximize their coding 
capacity including ribosomal frameshifts, overlapping reading frames, and alternative splicing. 
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Unlike simple retroviruses that generally only express two RNAs (full length and singly spliced), 
lentiviruses (and spumaviruses) are so called “complex” retroviruses due to their use of multiple 
alternative splice sites to express high numbers of different mRNA species that code for 
additional regulatory and accessory proteins (1).   
Some lentiviruses such as HIV-1 can generate up to 40 different mRNA species, however 
there are three basic classes of viral RNAs: full length RNA’s that are translated into Gag-Pol 
polyproteins or serve as new genomes; singly spliced RNA’s that are translated into the envelope 
proteins; and multi-spliced mRNAs that code for regulatory and/or accessory proteins. The 
cytoplasmic expression of unspliced and singly spliced mRNA species is temporally regulated by 
the Rev regulatory protein. The process and operations of Rev are best studied in HIV-1 (Figure 
2). Rev is translated from a mutispliced RNA, imports into the nucleus via binding to Importin- 
(2), and subsequently binds a structured RNA motif, known as the Rev responsive element 
(RRE), which is present in the unspliced and singly spliced mRNA. After initial binding, Rev 
multimerizes along the RRE (3, 4) in a cooperative fashion (5). Rev then tethers the viral RNA to 
the cellular CRM1 protein to mediate export of the RNA cargo through the nuclear pore and to 
the cytoplasm (6). 
The interaction between HIV-1 Rev and RRE is highly dependent on the secondary 
structure of the RRE (4, 7, 8). The HIV-1 RRE is a 351 nucleotide (nt) sequence that overlaps 
the intronic SU/TM border region (9). The HIV-1 RRE is a highly structured motif with stem 
regions labeled I-V (Figure 3). Early analysis indicated stem-loop II B (SLIIB) bound to Rev 
with similar affinity to the full RRE, at 1-3nM, suggesting SLIIB acted as the initial primary high 
affinity binding site for Rev (8, 10-13). The 17 amino acid (aa) arginine rich motif (ARM) of the 
Rev protein inserts into the major groove site in the bulge of SLIIB and widens the groove as 
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electrostatic interactions between the ARM and the RNA form (reviewed in (14)). After initial 
monomer binding, Rev subsequently oligomerizes through protein-protein and low affinity 
protein-RNA interactions along the RNA. While early models hypothesized SLIIB acted as the 
primary nucleation site for Rev binding and subsequent oligomerization, more recent studies by 
Daugherty et al.(15) identified Stem loop IA (SLIA) as a second high affinity Rev binding site 
capable of binding independent of SLIIB, however, neither site is capable of supporting nuclear 
export on its own.  
EIAV and Variation 
  Equine infectious anemia virus (EIAV) is a lentivirus related to HIV-1 and the other 
human and non-human primate lentiviruses (16). Infection of horses by EIAV causes a rapid and 
dynamic disease course. Experimental infections can result in acute viremia within 5-30 days. 
Thereafter, horses typically exhibit recurring cycles of fever, thrombocytopenia, viremia, and 
anemia anywhere from two months to one year after initial infection. While some horses exhibit 
prolonged initial clinical signs that can be fatal, most become clinically quiescent after the first 
year. This period of clinical quiescence, known as the inapparent stage of disease, is associated 
with low levels of viremia and the development of broadly acting immune responses believed to 
control, but not eradicate viral replication (reviewed in (17, 18)). This makes EIAV an excellent 
model to study factors involved in immunological control of lentivirus infections and 
mechanisms of viral persistence.   
Viruses employ a number of strategies to evade or even suppress the host immune 
response. In lentiviruses, antigenic variation of the HIV-1 envelope is a well-studied mechanism 
of immune evasion and represents a significant challenge to the development of an effective 
vaccine (reviewed in (19)). Antigenic variation in lentiviruses can result from a number of viral 
5 
 
and cellular mechanisms including: high error rate of reverse transcriptase (20, 21), 
recombination between viral genomes (22), and hyper-editing of viral genomes due to enzymes 
such as APOBEC3G (23). The EIAV surface (SU) envelope gene has been shown to be a highly 
variable region (24), and unique viral envelope variants are isolated from recurring febrile cycles 
(25-29) suggesting antigenic variation mediates immune escape. Later stage isolates also appear 
to be increasingly resistant to neutralizing antibodies (25, 29, 30).  
EIAV Rev  
In addition to variation in the SU region, significant genetic variation has been found in 
the Rev/TM overlapping reading frame (31-33). Unique dominant rev genotypes are found 
during different stages of disease (33). Phylogenetic analysis of Rev variants from 
experimentally infected horses indicated that variants clustered into two major clades; clade A 
comprised of chronic, inapparent, and late stage recrudescent Revs variants, and clade B 
comprised of mostly inoculum strain variants. Partition analysis of these groups indicated the  
two major subpopulations of Rev variants cycled in dominance over the course of infection, 
suggesting that each group varied in selective advantage (34). The presence of unique Rev 
genotypes and the expansion and contraction of subpopulations of Rev variants suggests Rev 
could facilitate immune evasion by regulating viral gene expression. In support of this, analysis 
of Rev activity during experimental EIAV infection indicated that changes in Rev export 
phenotype was associated with changes in stage of disease (33, 34).  
EIAV Rev is functionally homologous to HIV-1 Rev and regulates structural gene 
expression (31, 35). EIAV Rev is a 165 aa protein possessing a unique domain organization 
compared to the prototype HIV-1 (Figure 4). EIAV Rev includes a nuclear export signal (NES, 
aa 31-55)(36), a bi-partite RNA binding domain comprised of two small arginine rich motifs 
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(ARMs), with the second small C’-terminal ARM also functioning as the nuclear localization 
signal (NLS)(37). Mutations in HIV-1 Rev’s NES have been reported in asymptomatic HIV-1 
infected patients, leading to attenuated Rev export activity that is hypothesized to be involved in 
decreased viral replication (38). However, a majority of the genetic variation in EIAV Rev 
appears to localize outside the functional domain (32). The highest frequency of mutations in 
Rev occurs in a hypervariable region (aa range 105-142) just proximal to the second N-terminal 
ARM, and single point mutations in this region can alter Rev nuclear export phenotype (32). It is 
unclear how these mutations alter Rev nuclear export levels, however, multiple changes in this 
region alter the electrostatic charge of the local hypervariable region, which could feasibly alter 
the strength of the Rev-RRE interactions (32).  
Rev Structure 
Early modeling of the tertiary structure of EIAV Rev suggested that the two short ARMs 
of the bipartite RNA binding domain were positioned next to each other in the Rev monomer, 
forming a single binding RNA binding interface (39). However, more recent studies suggests 
that Rev could adopt an elongated structure placing the two short ARMs on opposing sides of the 
protein, preventing formation of a single RNA binding interface (40). Structure prediction and 
mutational analysis suggests that Rev dimerization is required for RNA binding. Docking 
prediction suggests that formation of the dimer juxtaposes RNA binding domain 1 from one Rev 
protein to RNA binding domain 2 of the second protein to form a single RNA binding interface 
on each side of the dimer (40). The details of how the protein interacts with the EIAV RRE are 
unclear. In particular, it is not known if dimerization of Rev results in two RNA interfaces, and if 
so, do both interfaces interact with distinct regions of the RRE? 
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EIAV RRE 
 Initial analysis indicated a 1700 nt sequence containing the majority of the envelope 
coding region, termed ERRE-All, possessed the highest Rev responsiveness in functional assays 
of export capacity (41). Subsequent mapping indicated that the first 555 nt of the ERRE-All,  
called ERRE-1, supported 52% the export activity of the full ERRE-All, while the remaining 
downstream sequence (termed ERRE-2) supported only 17% the activity of ERRE-All, 
suggesting ERRE-1 was the primary interaction site for Rev (41). ERRE-1 is located in the 5’ 
SU region of the envelope gene and spans Rev exon 1, unlike most characterized lentivirus 
responsive elements which do not overlap Rev coding regions and are located either at, or 
downstream of the SU/TM border,.           
ERRE-1 spans the first coding exon of Rev and contains a 56nt minRRE sequence which 
is the smallest sequence known to both bind Rev and support nuclear export (42). The minRRE 
contains guanine/adenine/purine (GAR) sequence repeats that serve as a binding site for Rev and 
as an exon splicing enhancer (ESE) necessary for the inclusion of exon three of the bi-cistronic 
RNA that codes for Tat and Rev (42, 43). EIAV Rev is translated from exon three and four of the 
bi-cistronic RNA. The presence of EIAV Rev is known to cause skipping of exon 3, resulting in 
Tat only mRNAs (43). In addition, mutation in the ESE affects both Rev binding and splicing of 
exon three (42). This suggests that Rev regulates exon 3 splicing by binding to the ESE and 
blocking splicing factors access to the ESE. Support for this competition model came from 
subsequent analysis that showed that increasing amounts of the SR protein SF2/ASF (involved in 
both constitutive and alternative eukaryotic splicing (44)) specifically inhibited Rev export 
activity and EIAV replication in a dose dependent fashion (42, 45).  
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Computational predictions combined with chemical probing analysis indicated the 
ERRE-1 sequence possessed a rather unstructured RNA topology (Figure 5)(46) compared to the 
highly ordered HIV-1 (10), FIV (47), and SIV (48) RRE secondary structures. Chemical 
footprint analysis of the RRE indicated that Rev interacted with two regions on the RRE, Rev 
binding region 1 (RBR-1) and Rev binding region 2 (RBR-2) (Figure 5)(46). RBR-1 spans Rev 
exon 1 and contains the minRRE/ESE sequence previously established to bind Rev and support 
nuclear export. The function of RBR-2 is not known. Like the HIV-1 RRE, RBR-2 is located in 
an envelope intronic region between rev exon 1 and 2. The EIAV Rev protein has a 19 nM 
binding affinity for the full ERRE-1 sequence. However deletion of RBR-2 results in ~250X 
decrease in Rev binding affinity for RRE (5.2 uM). In addition, unlike RBR-1 and the 
minRRE,which are highly unstructured, RBR-2 contains more stem structured regions 
reminiscent of the HIV-1 RRE. RBR-2 also contains predicted structural motifs similar to SLIIB 
which is also found in several other lentiviral genomes, suggesting a biological relevance for 
these structures (46). The requirement for high affinity binding and structural conservation data 
together suggests that RBR-2 could play a role in Rev mediated nuclear export and gene 
expression. Subsequent footprint analysis of SF2/ASF on the RRE indicated SF2/ASF bound two 
regions like Rev, with the first binding region partially overlapping RBR-1, and the second 
SF2/ASF binding site just prior to RBR-2 (45) (Figure 5). It is unclear how or if RBR-2 is 
involved in SF2/ASF-Rev functional competition, however, the fine mapping data of Rev and 
SF2/ASF on the RRE and the fact that RBR-2 facilitates Rev high affinity binding to the RRE 
could suggest RBR-2 provides Rev a competitive advantage for the RRE in competition with 
SF2/ASF.  
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Overall Objectives 
The overall objective of this study is to examine the role of RBR-2 in EIAV replication. 
We hypothesize that RBR-2 is involved in EIAV Rev mediated export and virus production, and 
that RBR-2 provides Rev a competitive advantage in SF2/ASF competition for the ESE/RRE. To 
test these hypotheses, we conducted the following  
1) Determine the effect of deleting RBR-2 on Rev mediated nuclear export and EIAV 
gene expression. 
2) Determine the effect of deleting RBR-2 on EIAV virion production 
3) Determine the effect of deleting RBR-2 on Rev-SF2/ASF competition.   
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Figures 
 
 
 
Figure 1. Cartoon depiction of retrovirus virion structure (adapted from (1)). Outer membrane consists of a lipid 
membrane embedded with SU/TM envelope trimers necessary for virus entry into a cell. Inner capsid proteins 
surround the two RNA genome copies and the rest of the viral structural and enzymatic proteins necessary to 
replicate upon entry into a target cell. CA = capsid, MA = matrix, NC = nucleocapsid, RT = reverse transcriptase, 
PR = protease, IN = integrase, SU = surface unit, TM = transmembrane protein.  
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Figure 2. Cartoon depiction of the cellular role of Rev in nuclear export. Depiction is based on HIV-1 Rev prototype 
(49). After transcription of the provirus, the viral pre-mRNA is spliced by the host spliceosome and exported to the 
cytoplasm. These mRNAs are translated into regulatory proteins such as Tat and Rev. Rev imports back into the 
nucleus, where it binds to the structured RNA element called the Rev responsive element (RRE) in partially spliced 
or unspliced viral RNA. Rev tethers these RNAs to nuclear export factors that then mediate transport of the RNAs to 
the cytoplasm, where they can be translated into the structural proteins of the virus or serve as new viral genomes.  
Picture is courtesy of Mike Belshan. 
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Figure 3. Predicted HIV-1 RRE secondary structure (15). Stem nomenclature is from (50) and numbering 
corresponds to (51). 
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Figure 4. Domain organization of EIAV Rev and HIV-1 Rev proteins. EIAV domain numbers according to (32, 40), 
HIV-1 domain numbers according to (49). Lengths are to relative scale. Abbreviations : NES = nuclear export 
signal, RBD = RNA binding domain, NER = non-essential region, NLS = nuclear localization signal.  
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Figure 5. Two distinct regions of the ERRE undergo structural transitions in the presence of bound EIAV Rev and 
SF2/ASF (reproduced from (45)). Consensus chemical modification patterns, based on at least 3 experiments in 
which several different primers were used to probe the complete ERRE RNA, mapped onto the RNA secondary 
structure. Ribonucleotides that consistently displayed enhanced modification with either kethoxal or DMS upon 
protein binding are circled: bold circle (strong) and thin circle (mild). Regions protected from hydroxyl radical 
cleavage in the presence of protein are denoted by a thick line. Purine-rich motifs are highlighted in green. Blue 
circles represent general areas modified in the presence of Rev, pink circles represent general areas modified in the 
presence of SF2/ASF.  
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 CHAPTER 2. FUNCTIONAL ANALYSIS OF REV BINDING REGION 2, A 
STRUCTURAL ELEMENT OF THE EIAV RRE 
 
Jerald Chavez, Hyelee Loyd, Drena Dobbs, Susan Carpenter  
 
 
Abstract 
Retrovirus replication depends on RNA-protein interactions that mediate key steps in the 
virus life cycle. In lentiviruses, nuclear export of incompletely spliced viral RNA requires 
interactions between the viral Rev protein and a viral sequence known as the Rev Responsive 
Element (RRE). In equine infectious anemia virus (EIAV), Rev binds two regions in the RRE, 
designated Rev-binding region-1 (RBR-1) and Rev-binding region-2 (RBR-2). RBR-1 is 
sufficient to mediate RNA export and overlaps an exonic splicing enhancer that binds the 
alternative splicing factor SF2/ASF. RBR-2 is structurally similar to other lentiviral RRE 
structures required for export, and is required for EIAV Rev high affinity binding to the RNA; 
however, the functional significance of RBR-2 is unknown. Here, we used Rev-dependent 
nuclear export assays and a Rev dependent EIAV virus gene expression assay to assess the role 
of RBR-2 in Rev dependent nuclear export and virus gene expression. There was no significant 
difference in export activity with or without RBR-2, whereas deletion of RBR-1 resulted in 
complete loss of nuclear export. Deletion of RBR-2 also had no effect on SF2/ASF inhibition of 
Rev activity in transient assays, suggesting RBR-2 does not provide a competitive advantage to 
Rev in the presence of SF2/ASF. Further, deletion of RBR-2 from the Rev dependent Gag/Pol 
expression construct did not result in any significant changes in to EIAV virus gene expression 
or virion production. Together, these results indicate RBR-2 does not play a role in Rev mediated 
nuclear export or virion replication.  
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Introduction 
 Equine infectious anemia virus (EIAV) is a lentivirus that primarily infects tissue 
macrophages (1). EIAV induces a rapid and dynamic clinical disease course. Initial acute 
viremia occurs 5-30 days post infection, followed by a chronic period characterized by repeated 
cycles of fever, thrombocytopenia, anemia, and viremia over a period of two months to one year. 
After, equids enter into the inapparent stage of disease, characterized by clinical quiescence and 
the development of a broadly acting immune response to control virus replication (reviewed in 
(2, 3)). However, like all lentiviruses, EIAV causes a lifelong persistent infection, and some 
inapparent carriers can recrudesce years to decades later. Therefore, EIAV is an excellent model 
to study both the mechanisms of lentiviral persistence and factors involved in immunological 
control of the virus.  
Due to their limited genome capacity, retroviruses utilize many strategies to maximize 
their coding capacity, including overlapping reading frames, ribosomal frameshifts, and 
alternative splicing. Lentiviruses translate the structural and enzymatic Gag, Pol, and Env 
proteins from unspliced and singly spliced mRNAs. Eukaryotes prevent release of incompletely 
spliced RNA through multiple forms of RNA surveillance including formation of retention and 
splicing complexes (RES) (4) and nonsense mediated decay (5, 6). Lentiviruses, encode the Rev 
protein for the export of unspliced/incompletely viral RNAs (vRNAs). Rev binds a cis-acting 
element in the viral RNAs known as the Rev responsive element (RRE)(7-9), multimerizes (10-
12), and tethers the RNA to the CRM1 nuclear export factor to mediate export of its cargo (13). 
Secondary structure is a primary determinant of interaction between Rev and the RRE (14-16) as 
mutations that disrupt key structural features can significantly reduce Rev binding (17-19). Early 
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analysis of the HIV-1 RRE secondary structure indicated Stem Loop IIB (SLIIB) was the 
primary binding site for Rev, though more recent analysis suggests that a secondary site, Stem 
loop IA (SLIA) can bind with similar affinity to that of SLIIB (20). Interaction between Rev and 
the RRE can induce structural changes in both the RNA and protein (21-23).  
 EIAV Rev is functionally homologous to the HIV-1 Rev protein. EIAV Rev is a 165 
amino acid (aa) protein, and possesses a unique structural domain organization, including an N-
terminal nuclear export signal (NES) and a bipartite RNA binding domain (RBD) (24). The 555 
nt EIAV RRE is located in the 5’region of envelope and overlaps with exon 1 of Rev. Two 
regions of the RRE have been shown to be structurally altered in the presence of Rev, Rev 
binding region 1 (RBR-1) and Rev binding region two (RBR-2) (Figure 1) (25). RBR-1 is 
located in Rev exon 1, lacks extensive secondary RNA structure, and contains a purine rich exon 
splicing enhancer (ESE) (26, 27) that overlaps a 57 nt sequence shown to be sufficient for export. 
The ESE region of RBR-1 contains binding sites for both Rev and alternative splicing factors, 
and mutations within this region have been shown to decrease both splicing between the flanking 
exons and binding of Rev to the RRE (26-28). Unlike RBR-1, RBR-2 is located in the envelope 
intronic region between Rev exon 1 and 2, and contains predicted structural motifs found in 
several other lentiviruses (25). In addition, deletion of RBR-2 resulted in ~250 fold decrease in 
Rev binding affinity for the RRE (25). The functional significance of RBR-2 is not known; 
however the structural conservation and requirement for high affinity binding suggests that RBR-
2 is involved in Rev mediated nuclear export. In this study, we explored the functional role of 
RBR-2 in Rev-dependent nuclear export and virion production.  
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Methods and Materials 
Cells  
HEK293T cells were plated in 12 well plates or in 6 well plates in Dulbecco’s Modified 
Eagles Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), Penicillin, 
Streptomycin, and L-glutamine and were kept at 37C with 5% CO2. Cells were transfected 24 
hours after seeding with plasmid DNA using TransIT-LT1 (Mirus). Media was changed 24 hours 
post transfection, and cells and supernatants were harvested 48 hours post transfection.   
Plasmid construction  
The plasmids pCH21SL, pERRE-1, pDM138 have been previously described (29, 30). 
pERRE-1B and pERRE-1C were constructed by PCR amplification of EIAV nt 5281 to 5624 
and nt 5606 to 5791 with primers containing Cla I restriction sites. The 5’ pERRE-1B primer 
was GGATCGATGGTTTGATATATGGGAGTA and the 3’ pERRE-1B primer was 
GGATCGATCCCTATATAATGTTGCTG (Cla I site underlined). The 5’ pERRE-1C primer 
was GGATCGATCAGCAACATTATATAGGG and the 3’ pERRE-1C primer was 
GGATCGATCTCTCTATGATAAGCTTC. Amplified fragments were purified, digested, and 
ligated to Cla I digested pDM138 vector.  
The EIAV provirus core plasmid, pEV53B, was previously described (31). To construct 
pEV53BRBR2, EIAV nt 2584-5586 (nt numbering based on CL22 genome, Genbank  
accession M87581.1) was PCR amplified with a forward primer upstream of a natural EcoRV 
site and a reverse primer containing a Hind III restriction site. The 5’ pEV53BRBR2 primer 
was ACAGCTTTCACTATTCCCTCC, and the 3’ pEV53BRBR2 primer was 
ACCCAAGCTTCCCTATATAATGTTGCTG (Hind III site underlined). Amplified fragments 
were purified, digested, and ligated to EcoRV-HindIII digested pEV53B.  
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 pSF2/ASF encodes the human SF2/ASF alternative splicing factor, and was previously 
described (27).  
Transient CAT Assays 
Chloramphenicol acetyltransferase (CAT) assays were carried out as previously 
described (29). Briefly, HEK293T cells were seeded in 12 well plates at 3 x 105 cells per well. 
Cells were co-transfected 24 hr post seeding with 50ng pCH21SL (Rev) or pCDNA3.1(–), 100ng 
of pCH110 (-Gal), 230ng pUC18, and 100ng of pDM138 CAT based reporter plasmid (32). At 
48 hr post transfection, cells were lysed by rapid freeze/thaw cycles in 0.2 ml 0.25M Tris buffer 
(pH 7.5). -Gal assays were performed with 50ul lystate to normalize for transfection efficiency. 
Normalized lysate volumes were assayed for CAT protein levels via a CAT ELISA (Roach # 11 
363 727 001). Results were normalized to pERRE-1, and results represent at least two 
independent transfections done in triplicate.  
SF2/ASF competition assays 
HEK293T cells were seeded in 12 well plates at 3 x 105 cells per well. Cells were co-
transfected 24hr post seeding with 50ng pCH21SL (Rev) or pCDNA3.1 – and 100ng of pCH100 
(-Gal), varying amounts of pSF2/ASF, 100ng of pDM138 CAT based reporter plasmid (32), 
and enough pUC18 to normalize to 650 ug total DNA transfected per well. CAT assays were 
carried out as above. Competition was measured by calculating the inhibitory dose of pSF2/ASF 
necessary to reduce Rev activity to 50% (ID50) of that observed in the absence of pSF2/ASF. 
Values were calculated using Graphpad Prism 6 software using a non-linear regression model. 
Significance was calculated by an unpaired T Test using the PRISM software program (Version 
6.01, Graphpad). 
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EIAV Gag Expression and Virion Production 
HEK293T cells were seeded at 7 x 105 cells per well in 6 well plates. At 24 hr post 
seeding, cells were transfected with varying amounts of pEV53B, pEV53BRBR2, or 
pEV53BRev and pUC18 was added to total 1.6 ug of DNA per well. Cells and supernatants 
were collected 48 hr post transfection. Cells were lysed with RIPA buffer (150 mM NaCl, 10 
mM NaPO4, 0.5% Triton X-100, 0.1% SDS, 0.5% SDS), and supernatants were clarified by 
centrifugation at 1000xg for 10min. 
For pseudovirus production, cells were co-transfected 24 hr post seeding with 1.6 ug  
pEV53B, pEV53BRBR2, or pEV53BRev and 1.6 ug pSIN6.1Luc (reporter genome) and 
pcDNAENV (EIAV19 envelope) as previously described (33). Supernatants were collected 48 hr 
post transfection and were clarified by centrifugation at 1000xg for 10min. 
Western Blots 
 Lysates and supernatants from transfected cells were harvested 48 hrs post transfection 
and 50ug of total protein from each lysate was resolved by SDS-PAGE (12% polyacrylamide) 
and transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were probed with 
either mouse anti-Gag 6A-1(Washington State University) hybridoma supernatant or mouse anti-
-Actin (SIGMA A1978) primary antibodies, and a peroxidase conjugated sheep anti mouse 
secondary antibody (Jackson Immuno Research #515-0350062). Secondary antibodies were 
visualized following incubation ECL substrate (Pierce # 32209). 
Virus-like particles (VLPs) were pelleted from clarified supernatants at 100,000 xg for 
1hr, resuspended in 40ul 1xPBS, and analyzed by Western Blot as described above.  
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RNA isolation & qRT-PCR 
For RNA isolation, 140ul of producer cell supernatant was DNase I treated using 1U of 
DNase I in a reaction volume of 160 ul with 1X DNase I reaction buffer (Invitrogen Cat# 18068-
015). After incubation for 15 min at room temperature, the reaction was stopped by adding 
EDTA to 2mM concentration in a final volume of 180 ul, and samples were heat treated at 65°C 
for 10min. A total of 180ul volumes of DNase treated supernatant was then used to isolate RNA 
using QIAamp Viral RNA mini kit (QIAGEN Cat# 52904) according to manufacturer’s 
protocols. RNA was eluted in 60 ul of elution buffer and 10 ul purified RNA was subjected to 
second DNAse I treatment and diluted to 100 ul with H2O.  
 Virion production was quantified by qRT-PCR for the firefly luciferase reporter RNA 
using RNA-to-Ct one step kit (Applied Biosystems # 4392938) according to manufacturer’s 
protocols. PCR reaction contained 8 ul of purified diluted RNA in 20ul volumes with the 
following primers and probes: 5’-TATGAAGAGATACGCCCTGGTT-3’, Reverse Primer : 5’-
GCCCATATCGTTTCATAGCTTC-3’, and FAM Probe : 5’- 
FAM/TATGAAGAGATACGCCCTGGTT-3’. The initial reverse transcriptase step included one 
round of 48C for 15 min, 95C for 10min, followed by 40 cycles of 95C for 10sec, 57C for 50sec. 
the standard curve was calculated from serial ten-fold dilutions of firefly luciferase plasmid 
DNA (108 to 102 copy/ul).  
Results 
RBR-2 is not essential for Rev-mediated nuclear export 
RBR-2 was previously shown to be required for high affinity binding to the EIAV RRE 
and contains a predicted structural motif found in several other lentiviral genomes, suggesting 
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biological relevance (25). To determine if RBR-2 plays a role in Rev mediated nuclear export, 
we utilized a CAT based reporter assay (29). EIAV RRE sequences containing RBR-1 or RBR-2 
were cloned into the pDM138 reporter plasmid (pERRE-1B or pERRE-1C respectively, Figure 
2). Nuclear export activity was normalized to wild type pERRE-1, which contains both RBR-1 
and RBR-2. Results indicated that nuclear export activity of pERRE-1B was equivalent to the 
activity of pERRE-1 (Figure 3A), indicating that deletion of RBR-2 does not diminish Rev 
export activity. In contrast pERRE-1C showed no export activity above the background of 
pDM138, demonstrating that RBR-2 alone is not able to mediate Rev-dependent nuclear export. 
Together, these results indicate that RBR-2 is neither sufficient nor necessary for Rev export 
activity in transient assays.  
 To confirm these results in a more virus like system, we utilized the pEV53B lentivirus 
vector system (Olsen, 1998) to examine the effect of RBR-2 deletion on EIAV Gag expression 
using varying amounts of Rev and pEV53B vector. Gag expression gradually increased as the 
amount of transfected pEV53B increased from 400 to 1600 ng (Figure 3B). In comparison, 
p53BRBR2 Gag expression over the same titration range appeared to be identical to pEV53B, 
indicating deletion of RBR-2 did not alter Gag expression (Figure 3B). To confirm that Gag 
expression was Rev-dependent, we constructed pEV53BRev, in which the second exon of Rev 
is deleted. As expected, significant amounts of Gag were not detected in cells transfected with 
pEV53BRev, indicating that Gag expression from pEV53B-based plasmids is Rev-dependent.  
Together, these results indicate deletion of RBR-2 from an EIAV-based vector had no effect on 
Gag expression. 
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RBR-2 is not required for Virion Production 
In addition to nuclear export, Rev has been suggested to have other roles in regulating 
virus gene expression, including translation and packaging (34). Therefore, we wished to 
determine if deletion of RBR-2 had any effect on virion production. Equal amounts of pEV53B 
or pEV53BRBR2 were transfected into 293T cells and both intracellular Gag expression and 
production of virus like particle (VLP) were analyzed using Western Blot (Figure 4a). Similar to 
the previous assays, deletion of RBR-2 had no effect on either intracellular Gag expression or 
VLP production. 
To further investigate if deletion of RBR-2 had any effect on packaging of viral genomes, 
we generated an EIAV pseudotyped reporter virus using the pEV53B and pSIN6.1Luc reporter 
plasmids (33). RNA was isolated from producer cell supernatants and luciferase RNA was 
quantified by qRT-PCR. Results indicated similar levels of packaged RNA in supernatant from 
cells transfected with pEV53B and pEV53BRBR2 (Figure 4B). pEV53BRev produced 1000 
fold less RNA in comparison to pEV53B and pEV53BRBR2, and levels equivalent to the 
negative control in which pUC18 is substituted for pEV53B. Therefore, deletion of RBR-2 had 
no effect on packaging. Together, these studies indicate that RBR-2 does not play a role in late 
stages of EIAV replication.   
Deletion of RBR-2 does not affect SF2/ASF mediated inhibition of Rev export activity  
The EIAV RRE overlaps an ESE required for exon 3 inclusion in EIAV mRNA (27, 28). 
Previous studies have shown that SF2/ASF can inhibit both Rev activity (27) and EIAV 
replication (35), and conversely Rev can inhibit SF2/ASF dependent splicing (26, 27). SF2/ASF 
may compete with Rev for binding to the RRE, as deletion of SF2/ASF RNA recognition motif 
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(RRM) abrogates inhibition of Rev activity and EIAV replication. Because RBR-2 is required for 
high affinity binding of Rev to the RRE, we hypothesized that RBR-2 may provide Rev a 
competitive advantage in the presence of SF2/ASF. To test this, we determined the effect of 
deleting RBR-2 on Rev export activity in the presence of increasing concentrations of SF2/ASF 
(Figure 5). SF2/ASF inhibited 50% the Rev export activity using ERRE-1 (ID50) with 95ng 
plasmid, while deletion of RBR-2 resulted in non-significant 1.3 fold decrease to 77ng 
(significance calculated by unpaired T Test), indicating RBR-2 does not provide Rev a 
competitive advantage for the RRE in the presence of SF2/ASF.  
Discussion 
Like other lentivirus RREs, RBR-2 is located an intronic region of the EIAV envelope 
gene and is required for Rev high affinity binding to the RRE. In addition, RBR-2 contains 
predicted structural motifs conserved across several other lentivirus (25). We hypothesized that 
RBR-2 was a component of the EIAV RRE and played a role in Rev mediated nuclear export 
and subsequent viral structural gene expression. However, the results showed that RBR-2 is 
neither necessary nor sufficient for nuclear export in transient assays, and deletion of RBR-2 
does not subsequently affect Gag gene expression or virus production. Therefore, the functional 
significance, if any, of RBR-2 is unknown.    
Early models of the HIV-1 Rev-RRE interaction suggested that Stem loop IIB acted as 
the primary high binding site for Rev (18, 36, 37), and upon binding, initiated a nucleation event 
wherein Rev multimerized across the RRE. However, more recent analysis using natively 
purified Rev has identified Stem loop IA (SLIA) as a second high affinity site that can bind Rev 
on its own and support multimerization (38). SLIIB or SLIA alone do not support nuclear export 
(38-40), suggesting that nuclear export requires additional sequences and/or structures from the 
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larger RRE acting in concert with these high affinity sites. Like the HIV-1 RRE, RBR-2 is 
located in the intronic region between Rev exon one and two. In addition, similar to SLIIB or 
SLIA, RBR-2 is required for high affinity binding, and does not support Rev-mediated nuclear 
export on its own. However, the result that deletion of RBR-2 does not affect Rev export activity 
at all is surprising considering that deletion of this region results in a 250 fold loss in Rev 
binding affinity to the RRE. We had previously reported significant genetic variation in the Rev/TM 
overlapping reading frame (29, 30, 41), and demonstrated that variation could alter Rev nuclear export 
activity (29). Further, changes in Rev export phenotype correlated with changes in clinical stages of 
disease, suggesting that Rev export phenotype may contribute to variant selection in vivo (41, 42).  Most 
of the variation in Rev occurred outside essential functional domains of Rev, and it is not clear how 
genetic changes alter Rev phenotype. Interestingly, variation in charged amino acids were commonly 
found in the non-essential region, located upstream of the second RNA binding domain. Many of these 
charged changes modulated nuclear export activity (30). The present studies were done using a single Rev 
genotype, and it is possible that charge changes in the Rev protein at or near the RNA binding domains of 
Rev could alter nuclear export capacity by changing the strength of ionic interactions at the protein-RNA 
interface. If so, RBR-2 could be more important for Revs with lower RNA binding affinities. Further 
analysis of export activity with and without RBR-2 using variant Revs with charge changes is necessary 
to explore this hypothesis.  
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Figures 
 
Figure 1. Two distinct regions of the ERRE undergo structural transitions in the presence of bound EIAV Rev 
protein. Consensus chemical modification patterns, based on at least 3 experiments in which several different 
primers were used to probe the complete ERRE RNA, mapped onto the RNA secondary structure. Ribonucleotides 
that consistently displayed enhanced modification with either kethoxal or DMS upon Rev binding are circled: bold 
circle (strong) and thin circle (mild). Regions protected from hydroxyl radical cleavage in the presence of Rev are 
denoted by a thick line. Purine-rich motifs are highlighted in green. Re-print of figure from (25). Shaded blue 
regions indicate general regions of structural alterations in the presence of Rev. The 56 nt MinRRE is outlined in 
yellow, with overlapping exon splicing enhancer position defined by dashed blue line.   
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Figure 2. A) Schematic of the pDM138 CAT reporter plasmid.  X indicates location of multiple cloning site for 
insertion of RRE sequences. B) Schematic of RRE sequences inserted into the pDM138 reporter construct. pERRE-
1 contains the 555nt ERRE-1 sequence previously described (27). pERRE-1B has a deletion of RBR-2, while 
pERRE-1 has a deletion of RBR-1. Nucleotide numbers are based on the pFL85 proviral clone (43). 
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Figure 3. RBR-2 is not necessary for Rev nuclear export activity or Gag expression. A) Rev nuclear export activity 
using pDM138 CAT reporter constructs containing the indicated RRE sequences was assessed in transient 
transfection assays in HEK293T cells as previously described (29). Experiments were performed in triplicate, and 
results represent at least 2 independent transfections. Results for each RRE are normalized to pERRE-1. B) Gag 
expression in HEK293T cells transfected with pEV53B, pEV53BRBR2, or pEV53BRev. Lysates were collected 
48 hr post transfection. Gag gene expression was measured via Western Blot using anti-Gag antibody or -Actin to 
confirm equal loading among samples. The site of EIAV gag gene products are indicated on the right. 
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Figure 4. RBR-2 is not required for virus like particle or virion production. A) Production of VLPs. 2ug of pEV53B, 
pEV53BRBR2, and pEV53BRev were transfected into HEK293T cells and harvested 48hrs post transfection. 
Supernatants were clarified, and VLPs were sedimented by ultracentrifugation, and analyzed by Western Blot. B) 
Production of pseudovirus. 1.6ug of pEV53B, pEV53BRBR2, and pEV53BRev were cotransfected with 0.8ug 
EIAV envelope and 1.6ug of pLUC luciferace reporter genome. Virion particles were collected from supernatants, 
lysed and quantified by qRT-PCR.  
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Figure 5. RBR-2 does not provide Rev a competitive advantage for RRE in the presence of SF2/ASF. The activity of 
pERRE-1 and pERRE-1B were measured using the CAT transient transfection assay in the presence of increasing 
amounts of pSF2/ASF. Assays were performed in triplicate, and results represent at least 2 independent 
transfections.  
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CHAPTER 3. GENERAL DISCUSSION 
 
While the HIV-1 Rev protein and RRE have been extensively examined, the EIAV Rev-
RRE interaction has not been well studied. Recent chemical probing and footprinting analysis of 
the EIAV RRE indicated EIAV Rev bound two separate regions of the RRE, termed RBR-1 and 
RBR-2 (1). RBR-1 contains sequences previously shown to be involved in Rev binding, nuclear 
export, and exon recognition (ESE) (2-4). The interaction of Rev with RBR-2 was previously 
functionally uncharacterized. Deletion of RBR-2 resulted in ~250 fold loss in Rev binding 
affinity for the RRE, and predicted structural motifs in RBR-2 are found in several other 
lentivirus genomes, suggesting biological relevance. We hypothesized that RBR-2 was involved 
in Rev mediated export and virion production, and would provide Rev a competitive advantage 
in competition with SF2/ASF. In contrast with this hypothesis, we found that deletion of RBR-2 
had no effect on Rev mediated nuclear export or virion production. Rather, RBR-1 retained the 
almost all of the export activity of ERRE-1 (both RBR-1 and RBR-2). In addition, deletion of 
RBR-2 had relatively little effect on Rev-SF2/ASF competition. The results are surprising 
considering that deletion of RBR-2 results in a 250 fold loss in Rev binding affinity to the RRE.  
Early reports from studies of the HIV-1 RRE identified stemloop IIB as the Rev high 
affinity binding site (5-8), however, more recent studies identified stemloop IA (SLIA) as a 
second Rev binding site with similar binding affinity (9). While both sites are necessary to 
facilitate maximum nuclear export activity, neither isolated stem can facilitate nuclear export on 
their own (9), suggesting that the binding of both stems and other structures in the RRE are 
necessary to facilitate nuclear export. In addition to two different RRE binding sites, Rev utilizes 
different sets of amino acids in the arginine rich motif (ARM) to interact with SLIIB and SLIA 
(9). RBR-2 of the EIAV RRE is required for Rev high affinity binding, contains structural stem 
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elements found in several other lentiviruses, and is located in the intron between the two coding 
exons of Rev, suggesting that this site, at the very least would be involved in, if not be required 
for nuclear export. Similar to SLIIB and SLIA, RBR-2 is unable to facilitate export independent 
of other cis-acting sequences in the RRE. In contrast to the comparison however, is that deletion 
of the entire RBR-2 sequence has no discernable effect on nuclear export or virion production, 
while mutation of SLIA or SLIID structure alone can significantly reduce nuclear export (9). The 
minRRE/ESE sequence in RBR-1 had previously been established to bind Rev and support 
export. However, compared to SLIB and SLIA, RBR-1 in the context of ERRE-1 maintains an 
unstructured RNA topology (1), more reminiscent of binding of a RNA recognition motif 
binding site (10). Because the minRRE also serves as an ESE (2-4), these structural constraints 
on the minRRE may be necessary to maintain the sequence/structure for binding to alternative 
splicing factors like SF2/ASF required inclusion of exon three of the bi-cistronic  RNA necessary 
for translation of Rev. While it is still unclear what the molecular details of the EIAV Rev-RRE 
interactions are, the current data suggests that if RBR-2 does have a role in virus replication, it is 
independent of RBR-1. In addition, previous data suggests EIAV Rev dimerization is necessary 
for RNA binding, and that dimerization could result in two independent RNA interfaces on 
opposing sides of the dimer (11), which could interact with different sites on the RNA. However, 
even if this is the case, the interaction with either of the two possible interfaces and RBR-2 is not 
apparently required for nuclear export or virion production. 
 We previously reported that unique Rev genotypes can be isolated from different stages 
of EIAV infection (12), and that partition analysis indicated that subgroups or quasispecies of 
Rev variants expanded and contracted during different stages of EAIV disease (13), suggesting 
that these Revs possessed a selective advantage that could facilitate immune evasion via 
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modulation of virus gene expression. In support of this, changes in Rev export phenotype 
correlated with changes in stage of disease (12). Natural variation in the hypervariable region of 
Rev proximal to the second ARM does frequently change electrostatic charge in the area and can 
alter export phenotype (14). It is possible that this change in export activity could reflect a 
change in the charge attraction of the protein interface to the RNA. Our analysis of RBR-2 and 
nuclear export utilized a single Rev amino acid variant, H21. This variant exhibits relatively high 
levels of nuclear export activity (15), which could reflect higher binding affinity for the RRE.  
Future Studies 
The studies in this thesis attempt to functionally characterize the role of RBR-2 in EIAV 
Rev nuclear export and Rev-SF2/ASF competition. The lack of effect on Rev export activity and 
virus gene expression by deletion of RBR-2 suggests RBR-2 does not serve a role in virus 
replication and that RBR-1 is the primary binding site necessary to support nuclear export. 
However, these studies utilized only a single Rev variant, H21, associated with relatively high 
activity (15). The fact that multiple charge changes in Rev near the N-terminal ARM are 
associated with changes in Rev activity suggests that these charge changes could alter nuclear 
export activity by changing binding affinity of Rev to the RRE (Appendix 1). To test this 
hypothesis, it would need to be established if changes in charge in the Rev HVR correlate with 
changes in binding affinity via a filter binding or gel shift assays. In addition, if changes in 
binding affinity affect export capacity, then it would suggest that Rev variants with different 
affinities for the RRE would behave differently with and without RBR-2. Specifically, Rev 
variants with higher binding affinities may rely less on binding to RBR-2 for nuclear export and 
more on the primary binding site in RBR-1, whereas Rev variants with lower affinities would 
require RBR-2 interaction to support a threshold of activity. This could be tested by comparing 
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and correlating the various mutations that alter charge in the Rev protein with changes in binding 
affinity and nuclear export activity in the presence and absence of RBR-2.  These studies would 
establish if there is a functional consequence of Rev RRE binding affinity and provide functional 
relevance and determine if RBR-2 is involved in nuclear export in the context of Rev variation.   
The possibility that Rev charge changes might alter binding affinity of Rev may also have 
a drastic effect on Rev-SF2/ASF competition. Our current model suggests that SF2/ASF is 
functionally competitive with Rev for binding to the RRE/ESE region (16). If charge changes 
affect export activity through changes in binding affinity, Revs with lower RRE binding 
affinities may require RBR-2 in order to efficiently compete with SF2/ASF. Further studies need 
to compare Revs with different binding affinities in SF2/ASF competition assays to determine if 
these changes in affinity have a functional significance. Subsequent analysis would need to 
address if Rev variants with lower RRE affinities require RBR-2 for maximum competition 
efficiency with SF2/ASF.  
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APPENDIX. EFFECT OF GENETIC VARIATION ON PREDICTED RNA 
BINDING INTERFACE OF REV PROTEIN 
 
 
Figure A1. Effect of genetic variation on predicted RNA binding interface of Rev protein. Rev Amino acid 
sequences (exon 2 only) were uploaded to Bind N Server (1) for RNA interface predictions. Dots represent identical 
residues to R1 Rev variant. Green colored residues are predicted not to bind to RNA, red colored residues are 
predicted to bind RNA. Rev export activity percentages are relative R1 variant and are based on previous data 
(2,3,4). Phylogenetic groups are based on (5). Domain abbreviation: NES =  nuclear export signal, RBD = RNA 
binding domain, NLS = nuclear localization signal.  
Activity of R1 Phylogenetic Group Rev Variant NES
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
100% Clade B R1 D P Q G P L E S D Q W C R V L R Q S L P E E K I S S Q T C I A R R H L G P G P T Q H T P S
95% G134D    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    -    -    -    +    -    +    -    +    +    +    -    -    +    +    -    -    +    +    -    +    +    +    +    +    +    +
100% R143H    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    -    -    -    +    -    +    -    +    +    +    -    -    +    +    -    -    +    +    -    +    +    +    +    +    +    +
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165% Clade A R71    +    +    +    +    +    -    +    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    - A    -    -    -    - D    -    -    -    +    -    -    -    +    -    -
200% H21    +    +    +    +    +    -    + G    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    -    -    +    -    -
160% Clade A R93    +    +    +    +    +    -    +    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    - A    -    -    -    - D    -    -    -    +    -    -    -    +    -    -
150% D135G    +    +    +    +    +    -    +    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    -    -    +    -    -
175% Clade B R51    +    +    +    +    +    -    +    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    -    -    -    - G    -    -    +    -    -    -    +    -    -
160% Clade A R72    +    +    +    +    +    -    +    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    -    -    - D    -    -    -    +    -    -    -    +    -    -
180% Q138R    +    +    +    +    +    -    +    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    -    -    +    -    -
150% Clade A R42    +    +    +    +    +    -    +    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    +    -    -    -    - A    -    +    -    -    -    +    -    -
160% Clade A R12    +    +    +    +    +    -    +    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    -    -    +    -    -
165% Clade A R53    +    +    +    +    +    -    +    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    -    +    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    -    -    +    -    -
Activity of R1 Phylogenetic Group Rev Variant Non-Essential RBD2/NLS
121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 145 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165
100% Clade B R1 H F R E D Q R G D F S A W G D Y Q Q A Q E R R W G E Q S S P R V L R P G D S K R R R K H L
95% G134D    -    -    +    -    -    -    +    -    -    -    -    -    - D    -    -    -    -    -    +    -    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
100% R143H    -    -    +    -    -    -    +    -    -    -    -    -    -    -    -    -    -    -    -    +    - H    +    -    -    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
N/A AADAA    -    -    +    -    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    +    -    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
95% Clade B R2    -    -    +    -    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    +    -    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
200% G110D    -    -    +    -    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    +    -    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
55% Clade B R26    -    -    +    -    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    +    -    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
50% Clade B R103    -    -    +    -    -    -    +    -    -    -    -    -    -    -    -    -    -    +    -    +    -    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
160% Clade A R32    -    -    +    -    -    -    +    -    -    -    -    -    - D G    +    - R    -    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
125% Clade A R17    -    -    +    -    -    -    +    -    -    -    -    -    - D G    +    - R    -    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
220% Clade A R4    -    -    +    -    -    -    +    -    -    -    -    -    - D G    +    - R    -    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
190% Clade A R45    -    -    +    -    -    -    +    -    -    -    -    -    - D G    +    - R    -    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
165% Clade A R71    -    -    +    -    -    - K    -    -    -    -    -    - D G    +    - R    -    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
200% H21 Y    -    +    -    -    -    +    -    -    -    -    -    +    - G    +    + R    -    +    -    + L    -    -    -    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
160% Clade A R93    -    -    +    -    -    - K    -    -    -    -    -    +    - G    +    + R    -    +    -    + H    -    -    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
150% D135G    -    -    +    -    -    -    +    -    -    -    -    -    +    - G    +    +    +    -    +    -    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
175% Clade B R51    -    -    +    -    -    -    +    -    -    -    -    -    +    - G    +    +    +    -    +    -    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
160% Clade A R72    -    -    +    -    -    - K    -    -    -    -    -    +    -    -    +    + R    -    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
180% Q138R    -    -    +    -    -    -    +    -    -    -    -    -    +    -    -    +    + R    -    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
150% Clade A R42    -    -    +    -    -    -    +    -    -    -    -    -    +    - G    +    + R    +    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
160% Clade A R12    -    -    +    -    -    -    +    -    -    -    -    -    +    - G    +    + R    +    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +      +    +    +    +    +    +    +    -
165% Clade A R53    -    -    +    -    -    - K    -    -    -    -    -    +    - G    +    + R    +    +    +    +    +    +    +    +    +    +    +    +    +    -    -    +    +    +    +    +    +    +    +    +    +    +    -
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